Long-term outcome of autologous stem cell transplantation in light chain deposition disease

被引:79
|
作者
Lorenz, Elizabeth C. [1 ]
Gertz, Morie A. [1 ]
Fervenza, Fernando C. [1 ]
Dispenzieri, Angela [1 ]
Lacy, Martha Q. [1 ]
Hayman, Suzanne R. [1 ]
Gastineau, Dennis A. [1 ]
Leung, Nelson [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA
关键词
light chain deposition disease; monoclonal gammopathy; paraproteinemia; renal dysfunction; stem cell transplantation;
D O I
10.1093/ndt/gfm918
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Light chain deposition disease (LCDD) is a systemic disorder characterized by deposition of non-amyloid monoclonal light chains. Renal dysfunction is a ubiquitous manifestation of the LCDD disease. Reports suggest that high-dose chemotherapy and autologous stem cell transplantation (ASCT) may be beneficial in the treatment of LCDD. However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD. Methods. Six patients with LCDD have been transplanted at our institution since 2001. Patients received dexamethasone alone, dexamethasone plus thalidomide or no chemotherapy prior to conditioning. All the patients underwent high-dose melphalan conditioning after stem cell mobilization. Results. Three of the six patients had concurrent multiple myeloma (MM), and one patient was on haemodialysis prior to transplantation. Four patients were male and two were female. The median age was 43.5 years with a median serum creatinine of 2.4 mg/dl and a median estimated glomerular filtration rate (eGFR) of 26.5 ml/min/1.73 m(2). Five patients survived ASCT and one died on Day 26 of transplantation. Median follow-up was 31.7 months (range 31.3-60.7 months) after ASCT. Of the surviving patients, all the five achieved a haematological response post-transplantation although two ultimately relapsed and required further chemotherapy. The eGFR of one patient declined with relapse and improved with treatment, while the eGFR of the second patient remained stable throughout relapse and treatment. The patient on haemodialysis prior to transplantation continued to require it afterward, but ultimately received a renal transplant. Median reduction in proteinuria was 92% and median improvement in eGFR was 95%. Of the four evaluable patients all achieved criteria for a renal response after ASCT. Conclusions. ASCT may be an effective therapy for renal dysfunction associated with LCDD. In cases where kidney dysfunction persists after ASCT, a haematological response may permit successful kidney transplantation with improved graft viability and decreased risk of recurrence.
引用
收藏
页码:2052 / 2057
页数:6
相关论文
共 50 条
  • [31] Long-term outcome of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (HL) in the ABVD therapeutic era
    Friedberg, Jonathan W.
    Sensenig, Elizabeth
    Kelly, Jennifer
    Oliva, Jamie
    Constine, Louis
    Becker, Michael
    Phillips, Gordon
    Liesveld, Jane
    Fisher, Richard I.
    Bernstein, Steven H.
    BLOOD, 2007, 110 (11) : 566A - 566A
  • [32] Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation.
    Srour, Samer A.
    Milton, Denai R.
    Bashir, Qaiser
    Mehta, Rohtesh S.
    Saini, Neeraj
    Ciurea, Stefan O.
    Popat, Uday R.
    Khouri, Issa F.
    Kebriaeil, Partow
    Delgado, Ruby
    Rondon, Gabriela
    Manasanch, Elisabet
    Patel, Krina
    Lee, Hans C.
    Shpall, Elizabeth J.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S238 - S239
  • [33] Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome
    Saini, Neeraj Y.
    Patel, Romil D.
    Varma, Ankur
    Bashir, Qaiser
    Delgado, Ruby
    Rondon, Gabriela
    Popat, Uday
    Hosing, Chitra
    Nieto, Yago
    Kebriaei, Partow
    Weber, Donna M.
    Thomas, Sheeba K.
    Lee, Hans C.
    Manasanch, Elisabet E.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    Patel, Krina K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) : E72 - E74
  • [34] Long-term outcome of hematopoietic cell transplantation for Wolman disease
    Tolar, Jakub
    Anna, Petryk
    Khan, Khalid
    Bjoraker, Kendra
    Jessurun, Jose
    Charnas, Lawrence
    Grabowski, Gregory
    Shapiro, Elsa
    Orchard, Paul
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S39 - S39
  • [35] Long-Term Survival after Autologous Stem Cell Transplantation in a Colombian Population
    Lucia Sossa, Claudia
    Antonio Salazar, Luis
    Maria Pena, Angela
    Gomez, Edgar
    Marcela Chalela, Claudia
    Leonardo Reyes, David
    Rosales, Manuel
    Sandoval-Sus, Jose
    Osma, Sonia
    Luna-Gonzalez, Maria
    Serrano, Sergio
    Ines Jimenez, Sara
    BLOOD, 2018, 132
  • [36] Treatment of multiple myeloma with autologous stem cell transplantation: a long-term observation
    Wach, M.
    Cioch, M.
    Jawniak, D.
    Brzozowski, A.
    Gromek, T.
    Kosicka, M.
    Legiec, W.
    Legiec, M.
    Malek, M.
    Manko, J.
    Walter-Croneck, A.
    Wasik-Szczepanek, E.
    Dmoszynska, A.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S152 - S153
  • [37] Autologous hematopoietic stem cell transplantation in Hodgkin's disease patients - Long-term outcome and prognostic factors in a single center experience
    Holowiecki, J
    Wojnar, J
    Giebel, S
    Krawczyk, M
    Kopera, M
    Kachel, L
    Stella-Holowiecka, B
    BONE MARROW TRANSPLANTATION, 2002, 29 : S86 - S87
  • [38] Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
    Wadehra, Navin
    Farag, Sherif
    Bolwell, Brian
    Elder, Patrick
    Penza, Sam
    Matt, Kalaycio
    Avalos, Belinda
    Pohlman, Brad
    Marcucci, Guido
    Sobecks, Ronald
    Lin, Thomas
    Andresen, Steven
    Copelan, Edward
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (12) : 1343 - 1349
  • [39] Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma
    Oliver-Caldes, Aina
    Soler-Perromat, Juan Carlos
    Lozano, Ester
    Moreno, David
    Bataller, Alex
    Mozas, Pablo
    Garrote, Marta
    Setoain, Xavier
    Arostegui, Juan Ignacio
    Yague, Jordi
    Tovar, Natalia
    Jimenez, Raquel
    Rodriguez-Lobato, Luis Gerardo
    Cibeira, M. Teresa
    Rosinol, Laura
    Blade, Joan
    Juan, Manel
    de Larrea, Carlos Fernandez
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [40] Treatment of multiple myeloma with autologous stem cell transplantation: a long-term observation
    Pokrovskaya, O.
    Mendeleeva, L.
    Alekseeva, I.
    Gaponova, T.
    Urnova, E.
    Gribanova, E.
    Varlamova, E.
    Kalinin, N.
    Gretsov, E.
    Savchenko, V.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S265 - S265